Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
59.82
-3.78 (-5.94%)
At close: Mar 6, 2026, 4:00 PM EST
60.60
+0.78 (1.30%)
After-hours: Mar 6, 2026, 7:40 PM EST
Arrowhead Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
| Revenue | 1,091 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 | Upgrade
|
| Revenue Growth (YoY) | 43539.24% | 23258.15% | -98.52% | -1.03% | 75.89% | 57.16% | Upgrade
|
| Gross Profit | 1,091 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 | Upgrade
|
| Selling, General & Admin | 157.5 | 138.5 | 113.44 | 104.08 | 132.44 | 85.44 | Upgrade
|
| Research & Development | 632.92 | 592.6 | 491.19 | 341.66 | 289.3 | 201.88 | Upgrade
|
| Operating Expenses | 790.41 | 731.1 | 604.63 | 445.74 | 421.74 | 287.32 | Upgrade
|
| Operating Income | 300.57 | 98.35 | -601.08 | -205 | -178.51 | -149.04 | Upgrade
|
| Interest Expense | -90.22 | -89.36 | -32.35 | -18.33 | - | - | Upgrade
|
| Interest & Investment Income | 39.38 | 37.29 | 22.72 | 15.3 | 5.03 | 6.12 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.2 | 5.26 | -1.75 | 1.54 | 0.77 | 2.07 | Upgrade
|
| EBT Excluding Unusual Items | 254.92 | 51.53 | -612.46 | -206.49 | -172.71 | -140.85 | Upgrade
|
| Pretax Income | 254.92 | 51.53 | -612.46 | -206.49 | -172.71 | -140.85 | Upgrade
|
| Income Tax Expense | 21.35 | 21.42 | -2.77 | 2.78 | 3.79 | 0 | Upgrade
|
| Earnings From Continuing Operations | 233.57 | 30.11 | -609.69 | -209.28 | -176.49 | -140.85 | Upgrade
|
| Minority Interest in Earnings | -31.31 | -31.75 | 10.2 | 4 | 0.43 | - | Upgrade
|
| Net Income | 202.27 | -1.63 | -599.49 | -205.28 | -176.06 | -140.85 | Upgrade
|
| Net Income to Common | 202.27 | -1.63 | -599.49 | -205.28 | -176.06 | -140.85 | Upgrade
|
| Shares Outstanding (Basic) | 137 | 134 | 120 | 107 | 105 | 104 | Upgrade
|
| Shares Outstanding (Diluted) | 138 | 134 | 120 | 107 | 105 | 104 | Upgrade
|
| Shares Change (YoY) | 10.94% | 11.67% | 12.21% | 1.26% | 1.62% | 3.00% | Upgrade
|
| EPS (Basic) | 1.48 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | Upgrade
|
| EPS (Diluted) | 1.48 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | Upgrade
|
| Free Cash Flow | 322.01 | 156.89 | -604.32 | -330.63 | -188.91 | 147.75 | Upgrade
|
| Free Cash Flow Per Share | 2.34 | 1.17 | -5.04 | -3.10 | -1.79 | 1.42 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 27.55% | 11.86% | -16927.06% | -85.16% | -73.39% | -107.77% | Upgrade
|
| Profit Margin | 18.54% | -0.20% | -16882.37% | -85.27% | -72.39% | -101.85% | Upgrade
|
| Free Cash Flow Margin | 29.52% | 18.92% | -17018.31% | -137.34% | -77.67% | 106.84% | Upgrade
|
| EBITDA | 325.65 | 122.27 | -582.49 | -192.51 | -168.09 | -140.77 | Upgrade
|
| EBITDA Margin | 29.85% | 14.74% | - | -79.97% | -69.11% | -101.79% | Upgrade
|
| D&A For EBITDA | 25.08 | 23.93 | 18.6 | 12.49 | 10.42 | 8.27 | Upgrade
|
| EBIT | 300.57 | 98.35 | -601.08 | -205 | -178.51 | -149.04 | Upgrade
|
| EBIT Margin | 27.55% | 11.86% | - | -85.16% | -73.39% | -107.77% | Upgrade
|
| Effective Tax Rate | 8.37% | 41.56% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.